Compounds with super-aspirin effects

US9670223B2 · kind B2 · utility

Assignee

• Solvotrin Therapeutics Limited · IE

Inventors

• John Gilmer · Dublin, IE
• Mark Ledwidge · Cork, IE
• Pat O'Flynn · Cork, IE
• Shona Harmon · Dublin, IE
• Marek Radomski · Dublin, IE
• Carlos Medina Martin · Dublin, IE

Key dates

• Filing date: Apr 8, 2015
• Grant date: Jun 6, 2017
• Expiry date: Apr 8, 2035

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A compound having the structural formula (I) and pharmaceutically acceptable salt and/or hydrates thereof, (I) wherein Y is an arylester or an C1-C8 alkylaryl ester, selected from the group consisting of: benzene, toluene, xylene, benzoic acid, benzoate, nicotinate, isonicotinate and halobenzene, which can be unsubstituted or substituted with at least one nitric oxide releasing group; and/or at least one of hydroxide, —Cl, —Br, a C1-C8 alkyl, benzyl, a C1-C8 alkoxy, benzyloxy, —NHC(O)R, —NH2, —NO2, —ONO2, —(CH2)nONO2, —OC(O)[(CH2)m], cyclic ONO2, —OCOArONO2, —OCOAr(CH2)nONO2 or a C1-C5 haloalkyl ester, wherein R is a C1-C8 alkyl or a C1-C8 alkoxy group, n=1-8 and m=3-10, to produce a super-aspirin effect.